Noumed Life Sciences Limited

Noumed Life Sciences Limited is a privately held pharmaceutical manufacturing company headquartered in Maidenhead, Berkshire, United Kingdom. Established in 2013 and operational since 2016, Noumed specializes in the development, manufacturing, and marketing of a diverse range of high-quality generic pharmaceutical products. Their portfolio spans various therapeutic areas, aiming to enhance patient care through accessible and effective medications.

The company operates from Noumed House, located at Shoppenhangers Road, Maidenhead, SL6 2RB. This facility houses their manufacturing, packaging, and quality control operations, ensuring compliance with Good Manufacturing Practice (GMP) guidelines. Noumed's services include intellectual property licensing, manufacturing, and research and development, leveraging both in-house capabilities and global partnerships to meet market demands.

Noumed Life Sciences Limited's distribution network is centered around its Maidenhead facility, which serves as the primary hub for manufacturing, packaging, and quality control. The on-site warehouse is fully equipped to store materials requiring cold storage conditions and has dedicated areas for controlled substances, ensuring compliance with regulatory standards.

While specific details about additional warehouse locations or logistics capabilities are not publicly disclosed, Noumed's strategic location in Maidenhead provides convenient access to major transportation routes, facilitating efficient distribution across the United Kingdom and potentially to international markets. The company's commitment to quality and regulatory compliance underscores its ability to manage a robust distribution network.

Noumed Life Sciences Limited plays a significant role in the United Kingdom's pharmaceutical supply chain as a pharmaceutical manufacturer. By developing and producing generic medications, Noumed contributes to increasing the availability of cost-effective treatment options within the UK market. Their focus on high-quality generics supports the healthcare system by providing alternatives to branded drugs, thereby enhancing patient access to essential therapies.

Additionally, Noumed's involvement in intellectual property licensing, manufacturing, and research and development indicates a comprehensive approach to pharmaceutical supply, encompassing both production and strategic partnerships to meet diverse market needs.

Noumed Life Sciences Limited's sourcing strategy reveals a high degree of concentration, with a total import value of $3.0 million USD from India over 70 shipments, primarily consisting of finished pharmaceutical formulations. The top three imported products—Fexofenadine, Erythromycin, and Propranolol—account for 69.8%, 15.8%, and 14.5% of the total import value, respectively. This indicates a focused product portfolio, with these three products comprising 100% of the company's imports from India.

The reliance on a limited number of products suggests a strategic choice to concentrate on high-demand medications within specific therapeutic categories. However, this concentration also exposes Noumed to potential supply chain risks, such as disruptions from Indian suppliers or fluctuations in product demand. The stability of their supplier relationships is crucial, as evidenced by the significant import values from suppliers like FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED ($3.2 million, 40.4% of total imports) and FOURRTS INDIA LABORATORIES PRIVATE LIMITED ($2.0 million, 24.8%). The high dependency on these suppliers necessitates robust risk management strategies to mitigate potential disruptions.

Noumed Life Sciences Limited's supply chain resilience is closely tied to its sourcing strategy from India. The company's import data indicates a heavy reliance on a few key suppliers, with FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED and FOURRTS INDIA LABORATORIES PRIVATE LIMITED accounting for a combined 65.2% of total imports. This concentration could pose risks in the event of supply disruptions or changes in supplier performance.

The limited number of unique formulations imported (174) suggests a focused product range, which may reduce complexity but also limits diversification. To enhance supply chain resilience, Noumed could consider diversifying its supplier base and increasing the number of formulations sourced. Additionally, establishing relationships with backup suppliers and exploring alternative sourcing options could mitigate potential risks associated with supplier dependency.

Noumed Life Sciences Limited's concentrated sourcing pattern positions the company to leverage economies of scale and maintain a focused product portfolio. This strategy allows for specialized expertise in specific therapeutic areas, potentially enhancing competitiveness in those segments. However, the high dependency on a limited number of suppliers and products exposes Noumed to supply chain vulnerabilities, such as disruptions from Indian suppliers or shifts in market demand.

For Indian exporters, this presents an opportunity to become alternative suppliers by offering products that align with Noumed's therapeutic focus. By ensuring consistent quality, reliability, and compliance with regulatory standards, Indian suppliers can position themselves as viable partners to Noumed, potentially expanding their market reach within the UK.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) serves as the primary regulatory authority overseeing pharmaceutical imports. The MHRA is responsible for ensuring that medicines meet appropriate standards of safety, quality, and efficacy before they are marketed in the UK. (gov.uk)

Key legislation governing pharmaceutical imports includes the Medicines for Human Use (Clinical Trials) Regulations 2004 and the Human Medicines Regulations 2012. These regulations outline the requirements for importing, manufacturing, and distributing medicinal products within the UK. The MHRA's guidance on sourcing medicines provides detailed information on the importation process, including licensing requirements and compliance with Good Manufacturing Practice (GMP). (gov.uk)

To import human medicines into the UK, companies must obtain a Wholesale Distribution Licence (WDA(H)) and, if applicable, a Manufacturer's Licence. Additionally, a Marketing Authorisation (MA) is required for each medicinal product to be marketed. These licences ensure that imported medicines meet the necessary standards for safety, quality, and efficacy. (gov.uk)

The MHRA recognizes GMP certificates from various authorities, including the European Union (EU), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certificates from recognized authorities to comply with UK regulations. (gov.uk)

Imported medicines must undergo batch testing to confirm their quality, safety, and efficacy. Stability studies are required to determine the shelf life and storage conditions of the products. Labeling must be in English and include essential information such as the product name, dosage form, strength, and instructions for use. Serialization mandates may apply to track and trace products throughout the supply chain, enhancing security and preventing counterfeit medicines. (gov.uk)

In December 2024, the MHRA updated its guidance on sourcing medicines for the UK market, reflecting new UK-wide licensing arrangements for human medicines that took effect on 1 January 2025 as part of the Windsor Framework. These updates include changes to licensing requirements, labeling, and packaging for imported medicines.

Noumed Life Sciences Limited's focus on importing finished pharmaceutical formulations from India, particularly in the therapeutic categories of Antihistamines & Allergy, Antibiotics, and Cardiovascular, aligns with market demand for cost-effective and accessible treatments in these areas. The top three imported products—Fexofenadine, Erythromycin, and Propranolol—are widely used medications, indicating a strategic approach to meet prevalent health concerns in the UK.

The company's concentrated product portfolio suggests a deliberate strategy to specialize in high-demand therapeutic areas, potentially enhancing expertise and competitiveness in these segments. This focus allows Noumed to streamline operations and maintain quality standards across a select range of products.

Noumed Life Sciences Limited's sourcing strategy emphasizes importing finished pharmaceutical formulations from India, leveraging the country's established manufacturing capabilities and cost advantages. The company's focus on specific therapeutic categories indicates a targeted approach to meet market needs. By maintaining a concentrated product portfolio, Noumed can ensure quality control and regulatory compliance, which are critical in the pharmaceutical industry.

Based on its product mix, Noumed Life Sciences Limited serves the United Kingdom market by supplying generic pharmaceutical products to various segments, including retail pharmacies, hospitals, and potentially government tenders. The company's focus on high-demand therapeutic areas positions it to address prevalent health concerns, thereby enhancing its presence in the UK's pharmaceutical supply chain.

There is a realistic opportunity for new Indian suppliers to partner with Noumed Life Sciences Limited, especially if they can offer products that align with Noumed's therapeutic focus and meet the required quality standards.